Table 1. Countries and study sites for each therapeutic efficacy study enrolling Plasmodium falciparum malaria–infected participants, 2016–2018.
| Country and study site | No. specimens at enrollment | Median age (range), y | Sex, % F |
|---|---|---|---|
| Ethiopia | 147 | 18.0 (1–65) | 32.9 |
| Arba Minch | 15 | 19.5 (10–54) | 50.0 |
| Pawe |
132 |
18.0 (1–65) |
31.3 |
| Kenya | |||
| Siaya |
332 |
2.7 (0.5–4.9) |
48.8 |
| Madagascar | 620 | 7.0 (0.2–15) | 47.1 |
| Ankazomborona | 168 | 8.3 (1.5–15) | 41.7 |
| Antsenavolo | 54 | 6.0 (0.2–14) | 53.7 |
| Kianjavato | 116 | 9.0 (0.3–15) | 46.6 |
| Matanga | 172 | 5.0 (0.3–15) | 48.3 |
| Vohitromby |
110 |
7.0 (1–15) |
50.9 |
| Rwanda | 218 | 3.3 (0.7–4.8) | 50.9 |
| Bugarama | 88 | 3.3 (0.8–4.8) | 52.3 |
| Masaka | 42 | 3.3 (0.8–4.0) | 54.8 |
| Rukara | 88 | 3.1 (0.7–4.8) | 46.6 |